Global Blood Therapeutics Inc (NASDAQ:GBT) Shares Purchased by Alps Advisors Inc.

Alps Advisors Inc. raised its position in Global Blood Therapeutics Inc (NASDAQ:GBT) by 1.7% in the 3rd quarter, Holdings Channel reports. The fund owned 119,641 shares of the company’s stock after purchasing an additional 1,969 shares during the period. Alps Advisors Inc.’s holdings in Global Blood Therapeutics were worth $5,805,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in Global Blood Therapeutics in the third quarter valued at approximately $125,000. Mackay Shields LLC grew its position in Global Blood Therapeutics by 2.8% in the third quarter. Mackay Shields LLC now owns 44,637 shares of the company’s stock valued at $2,166,000 after acquiring an additional 1,200 shares in the last quarter. California Public Employees Retirement System grew its position in Global Blood Therapeutics by 98.7% in the third quarter. California Public Employees Retirement System now owns 114,311 shares of the company’s stock valued at $5,546,000 after acquiring an additional 56,787 shares in the last quarter. Lindbrook Capital LLC grew its position in Global Blood Therapeutics by 133.3% in the third quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after acquiring an additional 400 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its position in Global Blood Therapeutics by 69.5% in the third quarter. Rice Hall James & Associates LLC now owns 235,762 shares of the company’s stock valued at $11,439,000 after acquiring an additional 96,642 shares in the last quarter. 97.85% of the stock is owned by institutional investors.

In other Global Blood Therapeutics news, insider De Dominicis Robert 490,012 shares of the stock in a transaction dated Tuesday, October 22nd. Also, insider Tricia Borga Suvari sold 3,249 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $48.70, for a total transaction of $158,226.30. Following the sale, the insider now directly owns 13,513 shares of the company’s stock, valued at approximately $658,083.10. The disclosure for this sale can be found here. Insiders have sold 14,698 shares of company stock valued at $711,058 in the last three months. Corporate insiders own 4.30% of the company’s stock.

GBT stock opened at $47.00 on Friday. Global Blood Therapeutics Inc has a twelve month low of $30.15 and a twelve month high of $64.94. The company has a current ratio of 16.79, a quick ratio of 16.79 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.99 billion, a P/E ratio of -13.78 and a beta of 1.57. The firm has a 50 day simple moving average of $49.25 and a 200-day simple moving average of $53.30.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.02). During the same period last year, the business earned ($0.83) EPS. On average, research analysts predict that Global Blood Therapeutics Inc will post -3.99 EPS for the current year.

Several analysts have issued reports on the stock. William Blair reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Global Blood Therapeutics in a research report on Wednesday, October 9th. Wedbush reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Global Blood Therapeutics in a research report on Wednesday, October 9th. SunTrust Banks increased their price objective on shares of Global Blood Therapeutics to $100.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Wells Fargo & Co increased their price objective on shares of Global Blood Therapeutics from $96.00 to $104.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $88.08.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Story: Dead Cat Bounce

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Leave a Reply

Your email address will not be published. Required fields are marked *

*